Effectiveness of Glucosamine + Chondroitin in Osteoarthrosis
Primary Purpose
Osteoarthrosis
Status
Completed
Phase
Phase 3
Locations
Brazil
Study Type
Interventional
Intervention
EMS Chondroitin Sulfate + Glucosamine Sulfate (Oral powder)
EMS Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg (hard capsules)
Zodiac: Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg (Oral powder)
Zodiac Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg (hard capsules)
Sponsored by

About this trial
This is an interventional treatment trial for Osteoarthrosis
Eligibility Criteria
Inclusion Criteria:
- Patients who agree with all aspects of the study and sign the Informed Consent;
- Patients of both sexes;
- Age above 30 years;
- Clinical and radiological diagnosis of osteoarthritis;
- Osteoarthritis in grades 1-2;
- Patients who are conducting medical treatment and that, for trial of Investigator, is eligible for the study.
Exclusion Criteria:
- Patients with a history of trauma clinically significant;
- Patients who underwent surgery on joints affected;
- Coexistence of diseases that might impede the successful conclusion of the trial (rheumatism and others);
- Pregnant patients and / or breastfeeding;
- Patients with phenylketonuria;
- Patients with clinical diagnosis of severe renal failure;
- Patients with clinical diagnosis of severe liver disease;
- Patients with clinical diagnosis of clotting disorders;
- Patients who are being treated with anti-aggregating and / or anticoagulants;
- Patients with sensitive components of the formula;
- Patients with emotional disorders that interfere with the capture of data;
- Patients who do not agree with the purposes of the study and did not sign the Informed Consent.
Sites / Locations
- Lal Clinica Pesquisa E Desenvolvimento Ltda
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm Type
Experimental
Experimental
Active Comparator
Active Comparator
Arm Label
Test 1
Test 2
Comparator 1
Comparator 2
Arm Description
Oral Powder EMS
Hard Capsules EMS
Oral Powder Zodiac
Hard capsules - Zodiac
Outcomes
Primary Outcome Measures
Decrease in pain.
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00860873
Brief Title
Effectiveness of Glucosamine + Chondroitin in Osteoarthrosis
Official Title
Randomized Study of Two Dosage Forms (Oral Powder and Capsule) of "Chondroitin + Glucosamine Sulfate" Produced by the Laboratory EMS When Compared to the Product Condroflex (Oral Powder and Capsules) Produced by Laboratory Zodiac in the Treatment of Osteoarthrosis.
Study Type
Interventional
2. Study Status
Record Verification Date
February 2013
Overall Recruitment Status
Completed
Study Start Date
October 2009 (undefined)
Primary Completion Date
November 2009 (Actual)
Study Completion Date
November 2010 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Azidus Brasil
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study objective is to check the non-inferiority of the 2 formulations produced by EMS when compared with the same substances and pharmaceuticals forms of the product Condroflex (Zodiac), by promoting the relief of osteoarthrosis symptoms such as pain, stiffness and functional capacity that will be periodically measured by using the "Visual Analog Scale" of pain (VAS) and the questionnaire of Lequesne.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteoarthrosis
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
280 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Test 1
Arm Type
Experimental
Arm Description
Oral Powder EMS
Arm Title
Test 2
Arm Type
Experimental
Arm Description
Hard Capsules EMS
Arm Title
Comparator 1
Arm Type
Active Comparator
Arm Description
Oral Powder Zodiac
Arm Title
Comparator 2
Arm Type
Active Comparator
Arm Description
Hard capsules - Zodiac
Intervention Type
Dietary Supplement
Intervention Name(s)
EMS Chondroitin Sulfate + Glucosamine Sulfate (Oral powder)
Intervention Description
Chondroitin Sulfate 1200mg Glucosamine Sulfate 1500mg
Intervention Type
Dietary Supplement
Intervention Name(s)
EMS Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg (hard capsules)
Intervention Description
Chondroitin Sulfate 1200mg Glucosamine Sulfate 1500mg
Intervention Type
Dietary Supplement
Intervention Name(s)
Zodiac: Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg (Oral powder)
Intervention Description
Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg
Intervention Type
Dietary Supplement
Intervention Name(s)
Zodiac Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg (hard capsules)
Intervention Description
Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg
Primary Outcome Measure Information:
Title
Decrease in pain.
Time Frame
V0 (Screening); V1 (Inclusion); V2 (2 weeks); V3 (4 weeks); V4 (8 weeks); V5 (12 weeks); V6 (24 weeks).
10. Eligibility
Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Patients who agree with all aspects of the study and sign the Informed Consent;
Patients of both sexes;
Age above 30 years;
Clinical and radiological diagnosis of osteoarthritis;
Osteoarthritis in grades 1-2;
Patients who are conducting medical treatment and that, for trial of Investigator, is eligible for the study.
Exclusion Criteria:
Patients with a history of trauma clinically significant;
Patients who underwent surgery on joints affected;
Coexistence of diseases that might impede the successful conclusion of the trial (rheumatism and others);
Pregnant patients and / or breastfeeding;
Patients with phenylketonuria;
Patients with clinical diagnosis of severe renal failure;
Patients with clinical diagnosis of severe liver disease;
Patients with clinical diagnosis of clotting disorders;
Patients who are being treated with anti-aggregating and / or anticoagulants;
Patients with sensitive components of the formula;
Patients with emotional disorders that interfere with the capture of data;
Patients who do not agree with the purposes of the study and did not sign the Informed Consent.
Facility Information:
Facility Name
Lal Clinica Pesquisa E Desenvolvimento Ltda
City
Valinhos
State/Province
Sao Paulo
ZIP/Postal Code
13270000
Country
Brazil
12. IPD Sharing Statement
Learn more about this trial
Effectiveness of Glucosamine + Chondroitin in Osteoarthrosis
We'll reach out to this number within 24 hrs